

Evaluation Report for Category B, Subcategories 2.1, 2.3, 2.4 Application

Application Number: 2022-2018
Application: New Manufacturing Concentrate (Product Chemistry) – Guarantee, Identity of Formulants, and Proportion of Formulants
Product: Liberty 180 SN Manufacturing Use Product
Registration Number: 35074
Active ingredient (a.i.): Glufosinate-ammonium
PMRA Document Number: 3537359

Purpose of Application

The purpose of this application was to register a new manufacturing concentrate, Liberty 180 SN Manufacturing Use Product, for manufacturing, formulating and repackaging use only.

Chemistry Assessment

Liberty 180 SN Manufacturing Use Product is formulated as a solution containing glufosinate-ammonium at a concentration of 180 g/L. This manufacturing use product has a density of 1.08-1.104 g/mL and pH of 6.5-8.5. The required chemistry data for Liberty 180 SN Manufacturing Use Product have been provided, reviewed and found to be acceptable.

Health Assessments

Liberty 180 SN Manufacturing Use Product is of low acute toxicity via the oral, dermal, and inhalation routes of exposure. It is extremely irritating to the eyes, mildly irritating to the skin and it is a dermal sensitizer.

Occupational and dietary exposure assessments were not required for this application.

Environmental and Value Assessments

Environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to support the registration of Liberty 180 SN Manufacturing Use Product.

References

PMRA

Document

Number

Reference

3353986	2021, BAS 1000 47 H: Determination of physico-chemical properties according to UN Transport Regulation and Directive 94/37/EC (Regulation (EC) No. 440/2008), DACO: 3.5.11,3.5.12,3.5.8
3353987	2021, Validation of the Analytical Method AFL1056/01: Quantitative Determination of the Active Ingredient Glufosinate-Ammonium in BAS 1000 47 H by Liquid Chromatography, DACO: 3.4.1
3353988	2021, Analytical Method AFL1056/01 - Quantitative Determination of the Active Ingredient Glufosinate-Ammonium in BAS 1000 47 H by Liquid Chromatography, DACO: 3.4.1
3353989	2021, BAS 1000 47 H: Determination of physico-chemical properties according to EPA Product Properties Test Guidelines, DACO: 3.5.8
3353992	2022, Physical and chemical properties of formula BAS 1000 47 H including Low temperature stability (7 days at 0C) and Accelerated storage stability (14 days at 54C), DACO: 3.5.1,3.5.10,3.5.14,3.5.2,3.5.3,3.5.6,3.5.7,3.5.9
3354008	2022, Miscibility, DACO: 3.5.13
3354009	2022, Dielectric Breakdown Voltage, DACO: 3.5.15
3354010	2022, Formulation Type of Liberty 180 SN Herbicide MP, DACO: 3.5.4
3354011	2022, Container Material and Description, DACO: 3.5.5
3511039	2023, LIBERTY(tm) SL 180 and LIBERTY(tm) SN 180 Amended Group A - Product Identity, Composition and Analysis, DACO: 3.2.1,3.2.2,3.2.3,3.3.1 CBI
3511040	2023, List of Report Amendments: LIBERTY(tm) SL 180 and LIBERTY(tm) SN 180: Amended Group A - Product Identity, Composition and Analysis. Amended Final Report Reg. Doc. No. 2023/2045557 , DACO: 3.2.1,3.2.2,3.2.3,3.3.1 CBI
3353994	2022, BAS 1000 47 H - Acute oral toxicity study in rats, DACO: 4.6.1
3353996	2022, BAS 1000 47 H - Acute dermal toxicity study in rats, DACO: 4.6.2
3353990	2022, BAS 1000 47 H - Acute inhalation toxicity study in Wistar rats - 4-hour liquid aerosol exposure (nose-only), DACO: 4.6.3
3353995	2022, BAS 1000 47 H - Acute eye irritation in rabbits, DACO: 4.6.4
3353997	2022, BAS 1000 47 H - Acute dermal irritation / corrosion in rabbits, DACO: 4.6.5
3353993	2022, BAS 1000 47 H - BUEHLER Test in guinea pigs, DACO: 4.6.6

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.